1,2-dipalmitoylphosphatidylcholine has been researched along with HIV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrieux, K; Bauduin, L; Bourgaux, C; Brisset, F; Caron, J; Chacun, H; Clayette, P; Couvreur, P; Degrouard, J; Dereuddre-Bosquet, N; Desmaële, D; Garcia-Argote, S; Gueutin, C; Lalanne, M; Paci, A; Rousseau, B; Skanji, R; Vassal, G | 1 |
| Beauchamp, D; Bergeron, MG; Désormeaux, A; Harvie, P; Makabi-Panzu, B; Perron, S; Poulin, L; Tremblay, M | 1 |
2 other study(ies) available for 1,2-dipalmitoylphosphatidylcholine and HIV
| Article | Year |
|---|---|
A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Oral; Animals; Anti-HIV Agents; Didanosine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Freeze Drying; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Liposomes; Nanostructures; Particle Size; Prodrugs; Rats; Rats, Wistar; Time Factors | 2011 |
Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2',3'-dideoxyinosine.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Analysis of Variance; Animals; Biological Transport; Cell Line; Cell Survival; Didanosine; Drug Carriers; Enzyme-Linked Immunosorbent Assay; Female; HIV; HIV Core Protein p24; Humans; Kinetics; Liposomes; Lymphoma, Large B-Cell, Diffuse; Macrophages; Male; Mice; Monocytes; Phosphatidylcholines; Phosphatidylglycerols; Rats; Rats, Sprague-Dawley; Time Factors | 1994 |